Goncharova Olga, Abrahamyan Arpine, Nair Divya, Beglaryan Mher, Bekbolotov Aibek, Zhdanova Elena, Kadyrov Abdullaat, Zachariah Rony
National Center of Phthisiology, Bishkek 720000, Kyrgyzstan.
Tuberculosis Research and Prevention Centre, Yerevan 0014, Armenia.
Trop Med Infect Dis. 2023 Jun 27;8(7):342. doi: 10.3390/tropicalmed8070342.
: Improving tuberculosis (TB) care in key populations is an operational research priority in the Kyrgyz Republic. Here, we describe the characteristics of TB/HIV co-infected individuals, their affiliations with key country-wide population groups, and their TB treatment outcomes. This was a cohort study using national programmatic data (2018-2022). The key population groups included people with increased exposure to TB, limited access to TB services, and increased risk of acquiring TB. Among 693 individuals with TB/HIV co-infection, the majority (58%) of individuals were from two regions of the Kyrgyz Republic (Chui and Bishkek). Eighty-four percent (84%) individuals had one or more affiliations to eight key population groups, with 49% of the individuals affiliated to ≥2 groups and 92% of the individuals were on both antiretroviral treatment and cotrimoxazole preventive therapy. Overall, 406 (59%) of the individuals had successful outcomes and 287 (41%) of the individuals had unsuccessful outcomes. Unsuccessful outcomes increased from 36% (n-39) with TB/HIV alone to 47% (n-86) with affiliations to ≥3 key population groups (-0.03). Unsuccessful outcomes were associated with co-morbidities (diabetes mellitus and hepatitis B/C), migration, alcohol use, and extrapulmonary TB. For a long time, people with TB/HIV co-infection have been recognized as a "double priority". Affiliation to key populations accentuates their status to "triple priority". We advocate for increased attention and equity towards these populations.
改善重点人群的结核病(TB)护理是吉尔吉斯共和国的一项行动研究重点。在此,我们描述了结核病/艾滋病毒合并感染个体的特征、他们与全国主要人群群体的关联以及他们的结核病治疗结果。这是一项使用国家规划数据(2018 - 2022年)的队列研究。主要人群群体包括结核病暴露增加、获得结核病服务机会有限以及感染结核病风险增加的人群。在693名结核病/艾滋病毒合并感染个体中,大多数(58%)个体来自吉尔吉斯共和国的两个地区(楚河州和比什凯克)。84%的个体隶属于八个主要人群群体中的一个或多个,49%的个体隶属于≥2个群体,92%的个体同时接受抗逆转录病毒治疗和复方新诺明预防性治疗。总体而言,406名(59%)个体治疗成功,287名(41%)个体治疗失败。仅患结核病/艾滋病毒时治疗失败率为36%(n = 39),隶属于≥3个主要人群群体时治疗失败率增至47%(n = 86)(P = 0.03)。治疗失败与合并症(糖尿病和乙型/丙型肝炎)迁移、饮酒和肺外结核有关。长期以来,结核病/艾滋病毒合并感染患者一直被视为“双重优先”人群。隶属于重点人群使他们的地位凸显为“三重优先”。我们主张对这些人群给予更多关注和平等对待。